Navigation Links
NIAID creates HIV vaccine discovery branch
Date:6/25/2008

To accelerate the translation of basic discoveries about HIV into advances in vaccine design and evaluation, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has formed a new Vaccine Discovery Branch within the Vaccine Research Program in the Division of AIDS (DAIDS).

"There is broad scientific consensus that designing a safe and effective vaccine to prevent HIV infection will require enormous advances beyond present-day knowledge," says NIAID Director Anthony S. Fauci, M.D. "The NIAID Vaccine Discovery Branch will help remove fundamental obstacles to achieving this goal by focusing intensively on the development and sharing of new knowledge critical to vaccine development."

The new branch is dedicated to monitoring scientific developments in multiple fields related to HIV vaccine discovery, building more bridges between basic researchers and HIV vaccine designers, identifying gaps in knowledge pertinent to a preventive HIV vaccine and promoting research to fill those gaps.

"Cross-fertilization of HIV/AIDS research with the fields of genetics, structural biology, systems biology and others could open up new perspectives on how to overcome major obstacles to HIV vaccine design," says DAIDS Director Carl W. Dieffenbach, Ph.D. "The Vaccine Discovery Branch will be in an ideal position to spot these opportunities, promote the translation of new knowledge about HIV and foster fruitful research collaborations."

In addition, the new branch will

  • Monitor vaccine discovery efforts and related basic HIV research within NIH, nationally and internationally

  • Determine funding priorities for vaccine discovery research

  • Plan, develop, implement and evaluate extramural grants and contracts to support the conduct of fundamental virology and immunology research as it relates to the discovery of novel AIDS vaccine concepts

  • Foster the development and supply of necessary research reagents and other resources

The Vaccine Discovery Branch also will have chief oversight of the Center for HIV/AIDS Vaccine Immunology (CHAVI), a consortium of universities and academic medical centers established by NIAID to solve major problems in HIV vaccine development and design. A multidisciplinary group of scientists from across DAIDS will continue to participate in overseeing CHAVI.

Jorge Flores, M.D., deputy director of the Vaccine Research Program, will serve as acting chief of the new branch until a national search results in the selection of a new chief. Dr. Flores has been involved in the conduct and administration of vaccine research at NIH since 1979.


'/>"/>

Contact: Laura Sivitz
sivitzl@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. NIAID funds $51M contract to create comprehensive model of immune responses
2. NIAID strengthens and expands Vaccine and Treatment Evaluation Units
3. NIAID scientists identify new cellular receptor for HIV
4. NIAID to convene HIV Vaccine Summit
5. NIAID describes research priorities to fight drug-resistant tuberculosis
6. NIAID to advance B-cell approach to HIV vaccines
7. S.C. BlueCross Creates Corporate Planning Unit, Promotes Davis to Vice President
8. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
9. Exceptional Childrens Foundation Merger with Kayne Eras Center Creates One of States Most Comprehensive Nonprofits Serving the Disabled
10. Prime Access Creates Groundbreaking Ads Targeting Urban Teens for the White Houses National Youth Anti-Drug Media Campaign
11. L.A. Playwright Creates an Enormous Wave with His New Book, Touch the Ocean
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... ... , ... HMP , a leader in healthcare events and education, today announced ... Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie ... competition recognizes editorial and design excellence across a range of sectors. This year’s program ...
(Date:10/12/2017)... RAPIDS, Mich. (PRWEB) , ... October 12, 2017 ... ... Wellness, has been named one of Michigan’s 2017 Best and Brightest in Wellness® ... and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in wound care advancements to physician colleagues, skilled nursing facility medical directors and ... the Treacherous Waters of Wound Care." , "At many of these conferences we ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... -- AVACEN Medical , Inc. (AVACEN) announced that Frost ... Product Innovation Award for Its fibromyalgia pain management device. ... device market research by Frost & Sullivan,s industry experts. ... relief product, the AVACEN 100, offers a safe and effective ... ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
Breaking Medicine Technology: